GlassScriptPhysician profile
William A Hodge
NPI 1811933518
$1,052,168.17
in general payments reported to CMS, 2019-2025
22 companies · $162K in 2025
The $162K reported for 2025 was more than what 98% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $211K · 2020: $107K · 2021: $107K · 2022: $130K · 2023: $152K · 2024: $183K · 2025: $162K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $338K · Grant: $56K · Consulting Fee: $52K · Charitable Contribution: $30K · Travel and Lodging: $14K · Food and Beverage: $5,368 · Education: $1,068.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $337,774.25 |
| Grant | $56,250.00 |
| Consulting Fee | $52,475.00 |
| Charitable Contribution | $29,836.77 |
| Travel and Lodging | $13,821.02 |
| Food and Beverage | $5,367.82 |
| Education | $1,068.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Encore Medical, LP | $871,478.63 | 2019-2025 | Djo Surgical |
| Shalby Advanced Technologies, INC. | $151,491.96 | 2021-2025 | Consensus Knee System, Cks - Vitalite, Consensus Hip System |
| Linkbio Corp | $19,217.37 | 2023-2024 | |
| Aesculap Implant Systems, LLC | $4,336.57 | 2021-2023 | Columbus Cr, As Columbus Cr, Corehip Primary |
| Zimmer Biomet Holdings, INC. | $3,336.13 | 2022-2025 | Persona, Rosa, Oxford |
| Stryker Corporation | $956.61 | 2021-2025 | Mako |
| Molnlycke Health Care US, LLC | $151.52 | 2024 | Mepilex Border Post-Op |
| Medtronic, INC. | $145.37 | 2021-2023 | Closurerfs |
| Orthalign INC | $136.99 | 2024 | Orthalign Plus |
| Sanara Medtech INC. | $126.81 | 2025 | Celleraterx |
| Vertex Pharmaceuticals Incorporated | $125.00 | 2025 | |
| Medical Device Business Services, INC. | $124.92 | 2024 | Vistaseal |
| Daiichi Sankyo INC. | $124.56 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $118.35 | 2024 | Exparel |
| Heraeus Medical, LLC. | $93.76 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $61.92 | 2024 | Redapt, Real Intelligence |
| Lima USA, INC. | $54.26 | 2021 | |
| Tracpatch Health, INC | $34.28 | 2021 | |
| Depuy Synthes Sales INC. | $21.46 | 2019 | |
| Solventum Corporation | $20.31 | 2024 | Prevena |
| Fidia Pharma USA INC. | $11.39 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$21,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Hodge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.